Gynecologic Cancer

Gynecologic Cancer

NRG-GY032

Official Title: A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)
Study Purpose: To determine if there are types of early-stage endometrial cancer that require less post-surgical treatment than the usual approach.
Status: Recruiting
Gynecologic Cancer

NRG-GY036

Official Title: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
Study Purpose: To study if the use of Olaparib for one year keeps your ovarian cancer from growing or returning as well as the usual approach of two years.
Status: Recruiting
Gynecologic Cancer

NRG-GY037

Official Title: A Phase III study of induction pembrolizumab and chemotherapy followed by pembrolizumab before chemoradiation and pembrolizumab maintenance compared to standard chemoradiation with pembrolizumab followed by pembrolizumab maintenance in high-risk cervical cancer
Study Purpose: To find out if adding an immunotherapy drug plus chemotherapy before starting the usual combination of chemotherapy and radiation will increase overall survival or improve recurrence-free survival from cervical cancer.
Status: Recruiting